Burixafor (TG-0054) vs Plerixafor

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: CXCR4 · full Multiple Myeloma pipeline

Burixafor (TG-0054)

Developed by GPCR Therapeutics, Inc. and partners

Phase 2 in Multiple Myelomasmall molecule
Weak signal

NCT01018979 · Phase 2 · completed

Although this study assigned patients to two dose levels, it had no placebo or active-comparator arm and was fully open-label (no masking), so there was no control against which to judge the drug's effect. Only 19 patients were treated, and most (13 of 19) dropped out before completing collection because their stem cell counts never rose high enough, leaving just 4 and 3 patients per dose group who even underwent apheresis for the primary mobilization-success endpoint. With no control arm and such a small, high-dropout sample, this is uncontrolled, exploratory evidence rather than a definitive efficacy trial.

Reported efficacy

Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5 (not_applicable)

Result source: NCT01458288

Plerixafor

Marketed by Sanofi

Approved in Multiple Myelomasmall molecule
Partial signal

NCT00103662 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 trial treated 302 patients with multiple myeloma with G-CSF plus plerixafor or G-CSF plus placebo for stem cell mobilization before autologous transplant. The primary endpoint was the percentage of patients who collected at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses. It was reached by 71.6% with plerixafor vs 34.4% with placebo (P<.001), so the primary was met. Source: DiPersio et al., Blood 2009.

Reported efficacy

Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis. (up to Day 6): Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009). (met)

Result source: NCT00103662

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBurixafor (TG-0054)Plerixafor
PFS, median—Not reported—Not posted · NCT00838357
OS, median—Not reported—Not posted · NCT00838357
ORR—Not reported—Not posted · NCT00838357
VGPR or better—Not reported—Not posted · NCT00838357
MRD negativity—Not reported—Not posted · NCT00838357

PFS, median

Burixafor (TG-0054)
—Not reported
Plerixafor
—Not posted · NCT00838357

OS, median

Burixafor (TG-0054)
—Not reported
Plerixafor
—Not posted · NCT00838357

ORR

Burixafor (TG-0054)
—Not reported
Plerixafor
—Not posted · NCT00838357

VGPR or better

Burixafor (TG-0054)
—Not reported
Plerixafor
—Not posted · NCT00838357

MRD negativity

Burixafor (TG-0054)
—Not reported
Plerixafor
—Not posted · NCT00838357
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Burixafor (TG-0054): 5 of 6 rows · Plerixafor: 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBurixafor (TG-0054)
Rows use multiple source trials
Plerixafor
Rows use multiple source trials
CD34 2e6 Mobilization
event count · % of participants
No placebo or comparator arm
89.5%a,b,c,d
NCT05561751 · Phase 2 · sponsor-reported, not registry data
96%a,b,c,d
NCT00838357 · Phase 3 · sponsor-reported, not registry data
1 other source trial
88% (n=25) @ 0.2857142857wk*
NCT04552743 · Phase 2 · registry result, not featured evidence · combination · converted to % from 22 Participants as posted
CD34 Target Achievement
event count · % of participants
No placebo or comparator arm
100% (n=7) @ 1wk*3.14 mg/kge,b,f
NCT01458288 · Phase 2 · monotherapy · converted to % from 7 participants as posted
show 1 more dose
100% (n=5) @ 1wk*3.14 mg/kg + G-CSF
NCT01458288 · Phase 2 · combination · converted to % from 5 participants as posted
75% (n=20) @ 0.714wk*b,f
NCT00901225 · Phase 2 · registry result, not featured evidence · combination · converted to % from 15 participants as posted
Dropout rate
76.9%3.14 mg/kgg
NCT01018979 · Phase 2 · monotherapy
show 3 more results
42.9%2.24 mg/kg
NCT01018979 · Phase 2 · monotherapy
—3.14 mg/kg IV
NCT01458288 · Phase 2 · monotherapy
—3.14 mg/kg
NCT02104427 · Phase 2 · registry result, not featured evidence · combination
12.8%h
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3
show 17 more results
—Arm D: PLERIXAFOR & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
0%
NCT04552743 · Phase 2 · registry result, not featured evidence · combination
6.1%
NCT02098109 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00998049 · Phase 2 · registry result, not featured evidence
4.8%
NCT00901225 · Phase 2 · registry result, not featured evidence · combination
0%Multiple Myeloma (MM)
NCT00396266 · Phase 2 · registry result, not featured evidence · combination
0%Non-Hodgkin's Lymphoma (NHL)
NCT00396266 · Phase 2 · registry result, not featured evidence · combination
6.5%Multiple Myeloma (MM)
NCT00322842 · Phase 2 · registry result, not featured evidence
50%Non-Hodgkin's Lymphoma (NHL)
NCT00322842 · Phase 2 · registry result, not featured evidence
—Multiple Myeloma (MM): Low CD34+ C
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Multiple Myeloma (MM): Plerixafor
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Multiple Myeloma (MM): Plerixafor
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Multiple Myeloma (MM): Plerixafor
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Non-Hodgkin's Lymphoma (NHL): Pler
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Non-Hodgkin's Lymphoma (NHL): Pler
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Non-Hodgkin's Lymphoma (NHL): Pler
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—3.14 mg/kgg
NCT01018979 · Phase 2 · monotherapy
show 3 more results
—2.24 mg/kg
NCT01018979 · Phase 2 · monotherapy
—3.14 mg/kg IV
NCT01458288 · Phase 2 · monotherapy
—3.14 mg/kg
NCT02104427 · Phase 2 · registry result, not featured evidence · combination
—h
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3
show 17 more results
—Arm D: PLERIXAFOR & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
—
NCT04552743 · Phase 2 · registry result, not featured evidence · combination
—
NCT02098109 · Phase 2 · registry result, not featured evidence · combination
—
NCT00998049 · Phase 2 · registry result, not featured evidence
—
NCT00901225 · Phase 2 · registry result, not featured evidence · combination
—Multiple Myeloma (MM)
NCT00396266 · Phase 2 · registry result, not featured evidence · combination
—Non-Hodgkin's Lymphoma (NHL)
NCT00396266 · Phase 2 · registry result, not featured evidence · combination
—Multiple Myeloma (MM)
NCT00322842 · Phase 2 · registry result, not featured evidence
—Non-Hodgkin's Lymphoma (NHL)
NCT00322842 · Phase 2 · registry result, not featured evidence
—Multiple Myeloma (MM): Low CD34+ C
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Multiple Myeloma (MM): Plerixafor
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Multiple Myeloma (MM): Plerixafor
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Multiple Myeloma (MM): Plerixafor
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Non-Hodgkin's Lymphoma (NHL): Pler
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Non-Hodgkin's Lymphoma (NHL): Pler
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
—Non-Hodgkin's Lymphoma (NHL): Pler
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
50%3.14 mg/kgg
NCT01018979 · Phase 2 · monotherapy
show 3 more results
28.6%2.24 mg/kg
NCT01018979 · Phase 2 · monotherapy
0%3.14 mg/kg IV
NCT01458288 · Phase 2 · monotherapy
0%3.14 mg/kg
NCT02104427 · Phase 2 · registry result, not featured evidence · combination
2.7%h
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3
show 17 more results
—Arm D: PLERIXAFOR & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
0%
NCT04552743 · Phase 2 · registry result, not featured evidence · combination
4.3%
NCT02098109 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00998049 · Phase 2 · registry result, not featured evidence
0%
NCT00901225 · Phase 2 · registry result, not featured evidence · combination
14.3%Multiple Myeloma (MM)
NCT00396266 · Phase 2 · registry result, not featured evidence · combination
12.5%Non-Hodgkin's Lymphoma (NHL)
NCT00396266 · Phase 2 · registry result, not featured evidence · combination
0%Multiple Myeloma (MM)
NCT00322842 · Phase 2 · registry result, not featured evidence
50%Non-Hodgkin's Lymphoma (NHL)
NCT00322842 · Phase 2 · registry result, not featured evidence
0%Multiple Myeloma (MM): Low CD34+ C
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
22.2%Multiple Myeloma (MM): Plerixafor
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
25%Multiple Myeloma (MM): Plerixafor
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
16.7%Multiple Myeloma (MM): Plerixafor
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
0%Non-Hodgkin's Lymphoma (NHL): Pler
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
0%Non-Hodgkin's Lymphoma (NHL): Pler
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
14.3%Non-Hodgkin's Lymphoma (NHL): Pler
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
3.14 mg/kgg
leukocytosis 16.7%
cardiac disorders-other:qt prolong at 24hr-36hr after infusion 8.3%
diarrhea 8.3%
NCT01018979 · Phase 2 · monotherapy
show 3 more results
2.24 mg/kg
dizziness 28.6%
leukocytosis 28.6%
abdominal pain 14.3%
NCT01018979 · Phase 2 · monotherapy
3.14 mg/kg IV
diarrhoea 33.3%
neuropathy peripheral 33.3%
abdominal pain 16.7%
NCT01458288 · Phase 2 · monotherapy
3.14 mg/kg
diarrhoea 8.3%
dry mouth 8.3%
hypokalaemia 8.3%
NCT02104427 · Phase 2 · registry result, not featured evidence · combination
h
bone pain 36.1% (placebo 42.4%)
nausea 34.7% (placebo 25.8%)
diarrhoea 32% (placebo 19.2%)
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3
show 15 more results
pain 52%
paresthesia 28%
nausea 24%
NCT04552743 · Phase 2 · registry result, not featured evidence · combination
bone pain 41.3%
lymphocyte count decreased 39.1%
platelet count decreased 39.1%
NCT02098109 · Phase 2 · registry result, not featured evidence · combination
nausea 43.6%
diarrhea 25.6%
dizziness 20.5%
NCT00998049 · Phase 2 · registry result, not featured evidence
febrile neutropenia 19%
NCT00901225 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 50%
bone pain 42.9%
catheter site erythema 42.9%
NCT00396266 · Phase 2 · registry result, not featured evidence · combination
back pain 50%
injection site erythema 50%
paraesthesia 50%
NCT00396266 · Phase 2 · registry result, not featured evidence · combination
hypokalaemia 16.1%
nausea 9.7%
pyrexia 9.7%
NCT00322842 · Phase 2 · registry result, not featured evidence
asthenia 25%
diarrhoea 25%
lymphadenopathy 25%
NCT00322842 · Phase 2 · registry result, not featured evidence
diarrhoea 100%
headache 100%
hypoaesthesia oral 100%
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
bone pain 77.8%
nausea 77.8%
catheter related complication 33.3%
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
back pain 50%
genital lesion 25%
kyphosis 25%
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
bone pain 58.3%
diarrhoea 50%
nausea 50%
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
thrombocytopenia 50%
back pain 33.3%
bone pain 33.3%
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
anal fistula 100%
catheter site erythema 100%
haemorrhoids 100%
NCT00322387 · Phase 2 · registry result, not featured evidence · combination
headache 71.4%
bone pain 57.1%
nausea 57.1%
NCT00322387 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fAssessment timepoints differ: 0.714 weeks versus 1 weeks.
  7. gPopulation comparability has not been reviewed for these studies.
  8. hPopulation comparability has not been reviewed for 17 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Burixafor (TG-0054)

Leukapheresis Sessions 2 count @ 1wk3.14 mg/kg
event count · count
No placebo or comparator arm
NCT01458288 · Phase 2 · monotherapy
show 1 more result
1.4 count @ 1wk3.14 mg/kg + G-CSF
NCT01458288 · Phase 2 · combination

Plerixafor

CD34 6e6 2 Days 0.716% (n=148) vs 0.344% (n=154) placebo @ 0.857wk
event count · % of participants
Proportion achieving target in ≤2 days
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3
CD34 6e6 4 Days 0.757% (n=148) vs 0.513% (n=154) placebo @ 1.143wk
event count · % of participants
Proportion achieving target in ≤4 days
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3
CD34 2e6 4 Days 0.953% (n=148) vs 0.883% (n=154) placebo @ 1.143wk
event count · % of participants
Proportion achieving target in ≤4 days
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3
Time to CD34 6e6 Median 0.03 vs 0.13 placebo months @ 1.143wk
time to event · months
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 1 days as posted
Time to PMN Engraftment Median 0.36 vs 0.36 placebo months @ 56.5wk
time to event · months
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 11 days as posted
Time to Platelet Engraftment Median 0.59 vs 0.59 placebo months @ 56.5wk
time to event · months
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 18 days as posted
show 1 more result
0.59 vs 0.57 Filgrastim (Neupogen) months*
NCT02098109 · Phase 2 · registry result, not featured evidence · combination · converted to months from 18 days as posted
Graft Durability 0.986% (n=142) vs 0.978% (n=136) placebo @ 14wk
event count · % of participants
Proportion of participants with a durable graft
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3
show 2 more results
0.985% (n=135) vs 0.984% (n=127) placebo @ 26wk
Proportion of participants with a durable graft
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3
0.992% (n=128) vs 0.992% (n=120) placebo @ 52wk
Proportion of participants with a durable graft
NCT00103662 · Phase 3 · combination · Multiple Myeloma · phase 3
Neutrophil Recovery 0 vs 100% VELCADE, CYCLOPHOSPHAMIDE, & G-CSF @ 2.86wk
event count · count
NCT01146834 · Phase 3 · registry result, not featured evidence
show 1 more result
0 vs 100% VELCADE, CYCLOPHOSPHAMIDE, & G-CSF @ 2.86wk
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
Platelet Recovery 0 vs 57.1% VELCADE, CYCLOPHOSPHAMIDE, & G-CSF @ 2.86wk
event count · count
NCT01146834 · Phase 3 · registry result, not featured evidence
show 1 more result
0 vs 57.1% VELCADE, CYCLOPHOSPHAMIDE, & G-CSF @ 2.86wk
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
Time to Neutrophil Engraftment 0.39 months
time to event · months
No placebo or comparator arm
NCT04552743 · Phase 2 · registry result, not featured evidence · combination · converted to months from 12 days as posted
Neutrophil Engraftment Maintenance 100% (n=19) @ 4.29wk
event count · % of participants
No placebo or comparator arm
NCT04552743 · Phase 2 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted
show 1 more result
100% (n=19) @ 14.29wk*
NCT04552743 · Phase 2 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted
Time to Platelet Engraftment Median 0.59 months
time to event · months
No placebo or comparator arm
NCT04552743 · Phase 2 · registry result, not featured evidence · combination · converted to months from 18 days as posted
show 2 more results
0.66 months*
NCT04552743 · Phase 2 · registry result, not featured evidence · combination · converted to months from 20 days as posted
0.62 months*
NCT00901225 · Phase 2 · registry result, not featured evidence · combination · converted to months from 19 days as posted

+ 19 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Burixafor (TG-0054)'s landscape · Plerixafor's landscape